![Quiver Logo](/static/img/logo-icon.png)
![ALVR logo](https://quiver-logos.s3.us-east-2.amazonaws.com/alvr.png)
AlloVir, Inc. Common Stock
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALVR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of ALVR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ALVR's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to ALVR
Recent picks made for ALVR stock on CNBC
ETFs with the largest estimated holdings in ALVR
Flights by private jets registered to ALVR
![Quiver Logo](/static/img/logo-icon.png)